PAPER Dickerson BC, Wolk DA,

Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.

Front Aging Neurosci. 2013;5:55. PubMed: 24130528

PAPER Schmidt MT, Kanda PA, Basile LF, da Silva Lopes HF, Baratho R, Demario JL, Jorge MS, Nardi AE, Machado S, Ianof JN, Nitrini R, Anghinah R

Index of alpha/theta ratio of the electroencephalogram: a new marker for Alzheimer's disease.

Front Aging Neurosci. 2013;5:60. PubMed: 24130529

PAPER Kim HJ, Kim J, Cho H, Ye BS, Yoon CW, Noh Y, Kim GH, Lee JH, Kim JS, Choe YS, Lee KH, Kim CH, Seo SW, Weiner MW, Na DL, Seong JK

Individual subject classification of mixed dementia from pure subcortical vascular dementia based on subcortical shape analysis.

PLoS One. 2013;8(10):e75602. PubMed: 24130724

PAPER Yoon SS, Jo SA

Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease.

Biomol Ther (Seoul). 2012 May;20(3):245-255. PubMed: 24130920

PAPER Lee YJ, Choi DY, Han SB, Kim YH, Kim KH, Seong YH, Oh KW, Hong JT

A Comparison between Extract Products of Magnolia officinalis on Memory Impairment and Amyloidogenesis in a Transgenic Mouse Model of Alzheimer's Disease.

Biomol Ther (Seoul). 2012 May;20(3):332-9. PubMed: 24130932

PSEN1(WT)

RESEARCH MODELS Summary These mice express wild-type human PSEN1. Compared with mice expressing similar levels of human PSEN1 with the P117L mutation (i.e. PSEN1(P117L), expression of wild-type PSEN1 was associated with increased survival and differentiation of neural pr

PSEN1(P117L) (line 13)

RESEARCH MODELS Summary Amyloid pathology is absent in these mice, but they have impaired neurogenesis. Specifically, the survival of BrdU-labeled neural progenitor cells was impaired leading to fewer newborn neurons. This effect was specific to expression of the mutant

PAPER Rösler N, Wichart I, Bancher C, Jellinger KA

Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia?

J Neural Transm Suppl. 1996;47:259-66. PubMed: 8841971

Liraglutide

THERAPEUTICS Novo Nordisk A/S Victoza™ Saxenda™ Other Other A study of liraglutide in 34 people with clinically diagnosed AD began in January 2012 at Aarhus University, Denmark. The primary outcome was change in cerebral amyloid deposition, measured by PiB-PET at base

Epothilone D

THERAPEUTICS Bristol-Myers Squibb BMS-241027 Small Molecule Tau In February 2012, Bristol-Myers Squibb started a Phase 1 trial to evaluate the tolerability and pharmacology of BMS-241027 in 40 patients with mild Alzheimer's disease whose MMSE at screening was bet

AZD3480

THERAPEUTICS AstraZeneca Targacept ispronicline TC-1734 Small Molecule Cholinergic System Referenced Condition:  Alzheimer's Disease US FDA Status:  Inactive Breaking News

Davunetide

THERAPEUTICS NAPVSIPQ Allon Therapeutics Inc. Paladin Labs Inc. NAP AL-108 Other Tau Four Phase 2 and 3 clinical trials were conducted with a nasal spray formulation of davunetide. From 2007–2008, a Phase 2 trial compared the effect on memory outcomes of 5 mg once a d

Karen Polyak

United States

Sandeep Saluja

Saran Ashram
India

PAPER Dec E, Rana P, Katheria V, Dec R, Khare M, Nalbandian A, Leu SY, Radom-Aizik S, Llewellyn K, Benmohamed L, Zaldivar F, Kimonis V

Cytokine Profiling in Patients with VCP-Associated Disease.

Clin Transl Sci. 2013 Oct 3; PubMed: 24119107